GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug
RegulatoryapprovedJideytroPositive
AI Analysis
Summary
GSK's FDA approval of Jideytro for lung cancer validates its $10.6B acquisition of Nuvalent Bio last month. GSK now has multiple lung cancer assets in late-stage development following the acquisition and a 2023 partnership with Hansoh Pharmaceutical.
Outcome Details
FDA approval of Jideytro for lung cancer
Importance:9/10
Sentiment:
0.90
FDA approvallung cancerM&AacquisitionNuvalentGSK
Read the original article
Published by BioSpace on July 23, 2026 11:59 AM